Authors: WELCH M SILVERS W SMITH J BAGCHI P WEHRLE L GALUCHIE L LEVY S

Citation: M. Welch et al., CLINICAL DOSE-RESPONSE STUDY OF AZMACORT(R) HFA-134A IN ADULT ASTHMATICS, Journal of allergy and clinical immunology, 99(1), 1997, pp. 1320-1320

Authors: LANGER CJ CATALANO R WEINER LM SCHER R BAGCHI P SAREN B COMIS RL

Citation: Cj. Langer et al., PHASE-II EVALUATION OF METHOTREXATE, VINBLASTINE, DOXORUBICIN, AND CISPLATIN (M-VAC) IN ADVANCED, MEASURABLE BREAST-CARCINOMA, Cancer investigation, 13(2), 1995, pp. 150-159

Authors: BAGCHI P JIANG O BONNEY GE

Citation: P. Bagchi et al., COMPOUND REGRESSIVE MODELS FOR QUANTITATIVE MULTIVARIATE PHENOTYPES -APPLICATION TO LIPID AND LIPOPROTEIN DATA, Genetic epidemiology, 10(6), 1993, pp. 647-651

Authors: LANGER CJ CURRAN WJ KELLER SM CATALANO R FOWLER W BLANKSTEIN K LITWIN S BAGCHI P NASH S COMIS R

Citation: Cj. Langer et al., REPORT OF PHASE-II TRIAL OF CONCURRENT CHEMORADIOTHERAPY WITH RADICALTHORACIC IRRADIATION (60 GY), INFUSIONAL FLUOROURACIL, BOLUS CISPLATIN AND ETOPOSIDE FOR CLINICAL STAGE IIIB AND BULKY IIIA NONSMALL CELL LUNG-CANCER, International journal of radiation oncology, biology, physics, 26(3), 1993, pp. 469-478

Authors: LANGER CJ ROSENBLUM N HOGAN M NASH S BAGCHI P LACRETA FP CATALANO R COMIS RL ODWYER PJ

Citation: Cj. Langer et al., INTRAPERITONEAL CISPLATIN AND ETOPOSIDE IN PERITONEAL MESOTHELIOMA - FAVORABLE OUTCOME WITH A MULTIMODALITY APPROACH, Cancer chemotherapy and pharmacology, 32(3), 1993, pp. 204-208